Diabetes and Its Economic Repercussions

Aisle Malone*

Department of Pathology and Laboratory Medicine, Temple University, Philadelphia

Corresponding Author*

Aisle Malone

Department of Pathology and Laboratory Medicine, Temple University, Philadelphia

E-mail: aisle@malone.com

Received: 01-July-2024, Manuscript No. jdm-24-33284; **Editor assigned:** 03-July-2024, PreQC No. jdm-24-33284; **Reviewed:** 17-July-2024, QC No. jdm-24-33284; **Revised:** 21-July-2024, Manuscript No. jdm-24-33284; **Published:** 28-July-2024, DOI: 10.35248/2155-6156.10001141

Abstract

Diabetes is a pervasive chronic disease with significant economic repercussions globally. This article examines the economic impact of diabetes, focusing on direct and indirect costs as well as broader societal implications. Direct costs include healthcare expenditures such as medical treatment, hospitalizations, medications, and professional care. Indirect costs encompass lost productivity due to absenteeism and presenteeism, disability, premature mortality, and the burden on informal caregivers. The strain on healthcare systems and the exacerbation of economic inequality are highlighted as broader societal consequences. The article underscores the necessity of comprehensive prevention, management, and policy interventions to mitigate the economic burden of diabetes and improve health outcomes.

Keywords: Diabetes; Economic impact; Healthcare costs; Lost productivity; Disability; Premature mortality; Informal caregiving; Healthcare system strain; Economic inequality; Prevention and management

Introduction

Diabetes is a chronic disease that affects millions of people worldwide. It poses a significant burden not only on individuals and their families but also on healthcare systems and economies. This article delves into the economic impact of diabetes, highlighting direct and indirect costs, as well as the broader societal implications [1-3].

Direct costs

Healthcare expenditures:

- **Medical treatment**: Diabetes management requires continuous medical attention, including regular doctor visits, blood sugar monitoring, and medications such as insulin. The cost of these treatments can be substantial.
- **Hospitalizations**: People with diabetes are at higher risk of complications that often lead to hospitalization, such as cardiovascular disease, neuropathy, and nephropathy. These hospital stays add significant costs to healthcare systems.

Medication and supplies:

- **Insulin and oral medications**: The cost of insulin and other diabetes medications can be prohibitive. In some countries, the price of insulin has soared, making it difficult for patients to afford their treatment.
- **Testing supplies**: Blood glucose monitors, test strips, and other supplies necessary for daily management add to the overall cost burden.

Professional care:

- **Specialist consultations**: Patients often require consultations with endocrinologists, dietitians, and other specialists, leading to additional expenses.
- **Long-term care**: Chronic diabetes complications may necessitate long-term care or nursing home admission, further escalating costs.

Indirect costs

Lost productivity:

- **Work absenteeism**: Diabetes and its complications can lead to frequent absenteeism, reducing overall productivity.
- **Presenteeism**: Even when present at work, individuals with diabetes may experience reduced efficiency due to symptoms like fatigue and the need for regular glucose monitoring.

Disability and premature mortality:

- **Disability**: Complications from diabetes can result in disabilities that limit a person's ability to work, leading to a loss of income and increased dependency on social support systems.
- **Premature death**: Diabetes is associated with a higher risk of premature death. The loss of life, especially among working-age individuals, can have a profound economic impact on families and society.

Informal caregiving:

- **Family impact**: Family members often need to provide care for loved ones with diabetes, which can result in lost wages and reduced economic productivity.
- **Psychosocial stress**: The stress and strain on caregivers can also contribute to indirect economic costs, including healthcare expenses for the caregivers themselves.

Broader societal implications

1. **Healthcare system strain**: The increasing prevalence of diabetes places a significant burden on healthcare systems, diverting resources from other essential health services.
2. **Economic inequality**: Diabetes disproportionately affects low-income populations, exacerbating existing health and economic disparities.
3. **Policy and prevention**: Investing in diabetes prevention and management programs can reduce long-term economic costs. Effective policies can help lower the incidence of diabetes and its complications, ultimately leading to cost savings for healthcare systems and improved quality of life for individuals.

Discussion

Economic burden on healthcare systems

Diabetes places an immense burden on healthcare systems worldwide. The costs associated with medical treatment, hospitalizations, medications, and specialist consultations are substantial and continuously rising. This strain diverts resources from other critical healthcare services, leading to potential gaps in care for non-diabetic patients. Additionally, the high cost of insulin and other essential diabetes medications highlights the need for more affordable treatment options to ensure that all patients can manage their condition effectively [4,5].

Indirect costs and productivity losses

The indirect costs of diabetes, particularly lost productivity, have far-reaching implications. Work absenteeism and presenteeism due to diabetes-related health issues reduce overall workforce efficiency and economic productivity. This can result in significant financial losses for businesses and the economy. Disability and premature mortality associated with diabetes further exacerbate these losses, as they lead to a reduction in the active working population and increased dependency on social support systems [6,7].

Impact on families and caregivers

Diabetes also imposes a significant burden on families and informal caregivers. The need for constant care and supervision can lead to lost wages and economic hardship for family members. The psychosocial stress experienced by caregivers can result in their own health problems, adding to healthcare costs. Policies that provide support for caregivers and ensure access to affordable care can help mitigate these indirect costs [8].

Societal implications and economic inequality

Diabetes disproportionately affects low-income populations, exacerbating existing health and economic disparities. Individuals in lower socioeconomic brackets often have less access to healthcare, healthy food options, and opportunities for physical activity, which can increase their risk of developing diabetes and its complications. Addressing these social determinants of health through targeted interventions can help reduce the prevalence of diabetes and its economic impact [9].

Prevention and management strategies

Investing in diabetes prevention and management is crucial for reducing the long-term economic burden of the disease. Public health initiatives that promote healthy lifestyles, early diagnosis, and effective management can prevent the onset of diabetes and its complications. Policies aimed at reducing the cost of diabetes medications and supplies can improve access to care and adherence to treatment regimens. Additionally, integrated care models that involve multidisciplinary teams can enhance patient outcomes and reduce hospitalizations [10].

Policy interventions

Effective policy interventions are essential for addressing the economic impact of diabetes. Governments and healthcare organizations must prioritize diabetes prevention and management in their health agendas. This includes funding for research, public health campaigns, and programs that target high-risk populations. Policies that promote affordable access to medications and healthcare services can alleviate the financial burden on individuals and families. Collaboration between public and private sectors can also drive innovation in diabetes care and management.

Conclusion

The economic impact of diabetes is profound and multifaceted, encompassing direct medical costs, indirect productivity losses, and broader societal implications. Addressing this impact requires a comprehensive approach that includes better prevention, management, and policy interventions. By investing in these areas, we can mitigate the economic burden of diabetes and improve outcomes for individuals and society as a whole.

References

1. American Diabetes Association Professional Practice Committee (2024) 16. Diabetes Care in the Hospital: Standards of Care in Diabetes-2024. Diabetes Care 47: S295.
2. Matthews DR, Cull CA, Stratton IM, Holman RR, Turner RC (1998) UKPDS 26: Sulphonylureas failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group. Diabet Med 15:297–303.
3. Turner RC (1998) The U.K. Prospective Diabetes Study: A review. Diabetes Care 21(Suppl 3): C35–C38.
4. Ehrenkranz JR, Lewis NG, Kahn CR, Roth J (2005) Phlorizin: a review. Diabetes Metab Res Rev 21: 31–38.
5. Cersosimo E (2014) Renal Glucose Handling and the Kidney as a Target for Anti-Diabetic Medication. Cur Trends Endocrinol 7: 81-94.
6. Monami M, Nardini C, Mannucci E (2014) Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 16: 457–466.
7. Handelsman Y (2019) Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes. Adv Ther 36: 2567-2586.
8. US Food and Drug Administration (2024) Sodium-glucose cotransporter-2 (SGLT2) Inhibitors.
9. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, et al. (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373: 2117–2128.
10. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, et al. (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377: 644–657.

Cite this article: Aisle Malone. Diabetes and Its Economic Repercussions. J Diabetes Metab, 2024, 15(7): 1141.